Clinical Heart Failure Management

Clinical Heart Failure Management
Written by
William T Abraham, John GF Cleland, Andrew JS Coats, Ewa Jankowska, Mitja Lainscak, Yury Lopatin, Marco Metra, Giuseppe MC Rosano, Petar Seferovic
ISBN
9781910303092
Published
March, 2017
Price
£39.99

Introduction

This book covers the recent advances in the diagnosis and the management of this rapidly growing cardiovascular subspecialty and provides an update on guideline-based management of heart failure.

Edited by renowned international experts, it is the most updated text on heart failure and a central resource for clinicians caring for patients with heart failure. It offers practical guidance that goes beyond the dry tables of the official guidelines and describes the background, the uncertainties and the newer treatments on the verge of practical implementation.

Author's Introduction

The increasing incidence and prevalence of chronic heart failure and our improving ability to identify its main pathophysiological mechanisms has been paralleled by remarkable improvements in medical and device therapy. The developments of new pharmacological and device therapies that have improved the prognosis of patients require a constant update on the overall management strategies of patients with heart failure. International guidelines for the diagnosis and management of heart failure have been recently updated with the most comprehensive and clinically oriented ones, the 2016 ESC/HFA guidelines for the diagnosis and treatment of acute and chronic heart failure, just recently released.

This book covers the recent advances in the diagnosis and the management of this rapidly growing cardiovascular subspecialty and provides an update on guideline-based management of heart failure. Edited by renowned international experts, it is the most updated text on heart failure and a central resource for clinicians caring for patients with heart failure. It offers practical guidance that goes beyond the dry tables of the official guidelines and describes the background, the uncertainties and the newer treatments on the verge of practical implementation.

Device therapies for heart failure with and without mechanical dys-synchrony are constantly in development and most of them have led to a significant improvement in the prognosis of patients with heart failure. This book provides basic knowledge about the modern device management of chronic heart failure and its guideline-based indications. The book also covers practical aspects of the management of patients with heart failure and provides a detailed resource for cardiologists and clinicians. With a strong focus on the medical management of chronic heart failure it is a key tool for optimally managing patients with complex co-morbidities.

Contents

Preface
List of editors and affiliations
1 Definition and classification of heart failure
2 Epidemiology and prognosis of heart failure
3 Clinical diagnosis in heart failure
4 Medical treatment of heart failure with reduced ejection fraction – prognostic indication
5 Medical treatment of heart failure with reduced ejection fraction – improving clinical status and functional capacity
6 Medical treatment of heart failure with reduced ejection fraction – aimed at reducing re-hospitalisations
7 Approach to the treatment of heart failure with preserved ejection fraction and mid-range ejection fraction
8 Treatment of patients in the vulnerable phase (at discharge or early after discharge)
9 Implantable cardioverter-defibrillators and cardiac resynchronization therapy in the treatment of heart failure with reduced ejection fraction
10 Management of arrhythmias in heart failure
11 Other devices – cardiac contractility modulation (CCM)
12 The potential of devices for HFpEF
13 The management of diabetic patients with heart failure
14 The management of heart failure in kidney and urinary tract syndromes
15 The management of co-morbidities in patients with heart failure – angina and coronary disease
16 The management of co-morbidities in patients with heart failure – hypertension
17 Valvular heart disease in heart failure
18 The management of co-morbidities in patients with heart failure – lung disorders
19 The management of co-morbidities in patients with heart failure – obstructive sleep apnoea
20 The management of co-morbidities in patients with heart failure – central sleep apnoea
21 The management of co-morbidities in patients with heart failure – potassium balance
22 The management of co-morbidities in patients with heart failure – iron deficiency

Sample Chapter

Chapter 6

Medical treatment of heart failure with reduced ejection fraction – aimed at reducing re-hospitalisations

Predicting heart failure readmission
Disease management programs
Medical therapy aimed at reducing hospitalisations

Management of fluid overload
Renin-angiotensin-aldosterone system inhibitors (RAASi)
Beta-blockers
Angiotensin II Receptor Neprilysin Inhibitor

About the Authors

William T Abraham
Director of the Division of Cardiovascular Medicine
Professor of Internal Medicine, Physiology and Cell Biology
The Ohio State University Wexner Medical Center, USA

John GF Cleland
Professor of Clinical Cardiology
Imperial College, London, UK
Andrew JS Coats
Joint Academic Vice-President
University of Warwick, UK
and Monash University, Australia

Ewa Jankowska
Professor and Head of Laboratory of Applied Research on Cardiovascular System
Wroclaw Medical University, Poland

Mitja Lainscak
Head of the Research and Education Department
General Hospital Celje, Slovenia

Yuri Lopatin
Professor and Head of Cardiology Department
Volgograd Regional Cardiology Centre, Russia

Marco Metra
Professor of Cardiology
University of Brescia, Italy

Giuseppe MC Rosano
Professor of Pharmacology, Consultant Cardiologist
St George’s Hospital NHS Trust, London, UK
and Scientific Director
Nutramed Consortium
Rome, Italy

Petar Seferovic
Professor of Internal Medicine – Cardiology
Deputy Director of the Polyclinic of the Clinical Centre of Serbia
Belgrade, Serbia